摘要
结直肠癌(CRC)是世界上最常见的癌症之一.。在过去的十年中,靶向治疗的发展给了转移性结直肠癌(mCRC)管理的一个癌症治疗新方向,并丰富了本病管理的治疗设备。在mCRC中,基于bevacizumab在临床试验中带来的最受欢迎的生存受益,通过血管内皮生长因子(VEGF)途径进行靶向的血管再生术已经引起了人们特别关注。最近,大型III期试验表明新抗血管增生药物aflibercept和regorafenib有临床效果 。然而,其它抗血管增生药物的临床前与临床研究结果却令人失望。 此外,血管增生抑制剂(AIs)在未筛选病人人群中表现出了温和这一优点。因此,深入研究预测生物标记物是必要的,但是到目前为止都失败了。然而,aflibercept和regorafenib被证明有益于bevacizumab单纯性和难治性病人,可能会反转AIs的获得性耐药性。这篇综述描述了mCRC中AIs发展的最近进展,特别关注了aflibercept和regorafenib,临床试验中这些药物评价所存在的挑战和设计发现临床有意义的生物标记物临床试验的潜在战略。
关键词: 结直肠癌,血管再生术,血管增生抑制剂,生物标记物,血管内皮生长因子(VEGF),bevacizumab
Current Drug Targets
Title:Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Volume: 18 Issue: 1
Author(s): Khurum Khan, David Cunningham, Ian Chau
Affiliation:
关键词: 结直肠癌,血管再生术,血管增生抑制剂,生物标记物,血管内皮生长因子(VEGF),bevacizumab
摘要: Colorectal cancer (CRC) is one of the commonest cancers in the world. During the last decade, the development of targeted therapies has given cancer treatment a novel direction in management of metastatic CRC (mCRC) and has enriched the therapeutic armamentarium in the management of this disease. In mCRC, targeting angiogenesis via the vascular endothelial growth factor (VEGF) pathway has been of particular interest based on the favourable survival benefit demonstrated by bevacizumab in clinical trials. More recently, large phase III studies have shown clinical efficacy for the new antiangiogenic agents aflibercept and regorafenib. However, the results of pre-clinical and clinical studies of other anti-angiogenic agents have been disappointing.
Furthermore, the benefits from angiogenic inhibitors (AIs) in an unselected patient population are modest. Research into predictive biomarkers is therefore essential, but has, to date, been unsuccessful. Nevertheless, aflibercept and regorafenib have been shown to benefit both bevacizumab naive and refractory patients, suggesting that acquired resistance to AIs can be potentially reversed. This review describes the most recent advances in development of AIs in mCRC with particular focus on aflibercept and regorafenib, the existing challenges for the evaluation of these agents in clinical practice and potential strategies in designing clinical trials that could lead to the discovery of clinically meaningful biomarkers.Export Options
About this article
Cite this article as:
Khurum Khan, David Cunningham, Ian Chau , Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions, Current Drug Targets 2017; 18 (1) . https://dx.doi.org/10.2174/1389450116666150325231555
DOI https://dx.doi.org/10.2174/1389450116666150325231555 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cellular Targets for Anticancer Strategies
Current Drug Targets TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Current Drug Targets Therapeutic Exploitation of Apoptosis and Autophagy for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Melatonin Enhances Anti-tumoral Effects of Menadione on Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells
Current Pharmacogenomics and Personalized Medicine CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery Ganoderma lucidum (Ling-zhi): The Impact of Chemistry on Biological Activity in Cancer
Current Bioactive Compounds Main Anti-tumor Angiogenesis Agents Isolated From Chinese Herbal Medicines
Mini-Reviews in Medicinal Chemistry In Vivo DNA Electrotransfer for Immunotherapy of Cancer and Neurodegenerative Diseases
Current Drug Metabolism Chitosan and Wnt/β-catenin Signaling Pathways in Different Cancers
Combinatorial Chemistry & High Throughput Screening Commercially Available, FDA-approved Epigenetic Modifiers As Therapeutic Agents in Bacterial Infection
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Imidazoquinolines: Recent Developments in Anticancer Activity
Mini-Reviews in Medicinal Chemistry Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Current Drug Targets Vitamin D, Pit-1, GH, and PRL: Possible Roles in Breast Cancer Development
Current Medicinal Chemistry Chitosan Nanoparticles: An Approbative System for the Delivery of Herbal Bioactives
The Natural Products Journal Disruption of Cell Death Signaling in Cancer: Impact on Disease Prognosis and Response to Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents
Current Pharmaceutical Design Genes Associated with Epithelial-Mesenchymal Transition: Possible Therapeutic Targets in Ductal Pancreatic Adenocarcinoma?
Anti-Cancer Agents in Medicinal Chemistry Progress in the Discovery of Polo-like Kinase Inhibitors
Current Topics in Medicinal Chemistry Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A
Current Medicinal Chemistry